Biologics Co. Execs Hit With Suit Over Revenue Controls
A shareholder of drug and medical device company Bioventus Inc. has alleged in a derivative suit that top brass damaged the company by artificially inflating revenues with "haphazard" accounting methods....To view the full article, register now.
Already a subscriber? Click here to view full article